Back

Relation of apolipoprotein C3 to risk of major adverse cardiovascular events and death after acute coronary syndrome on a background of optimized statin treatment

31 August 2024 (16:00 - 16:40)
Organised by: Logo
Congress Presentation Part of: Acute coronary syndromes: diagnosis, outcomes, and predictors Biomarkers ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Gregory Schwartz

University of Colorado School of Medicine, Aurora (United States of America)

6 More presentations in this session

Presentation thumbnail
Comparative analysis of vitamin K antagonists and direct oral anticoagulants for left ventricular thrombus management: a retrospective study utilising TriNetX
Doctor Z. Yao (Manchester, GB)
Abstract Slides Video
Presentation thumbnail
Early improvement in left ventricular microvascular flow post sonothrombolysis is associated with better left ventricular systolic function in st elevation myocardial infarction patients
Doctor L. Azevedo (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Growth differentiation factor-15 and 5-years cardiovascular risk in chest pain patients presenting to the emergency department: a multicenter cohort study
Doctor L. Crisanti (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Impact of neutrophil-to-lymphocyte ratio on clinical outcomes in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention
Doctor A. Oliva (New York, US)
Abstract Slides Video
Presentation thumbnail
N-terminal prohormone of brain natriuretic peptide predicts recurrent cardiovascular events in patients with acute coronary syndrome both in the acute and post-discharge setting: a TRACER substudy
Associate Professor G. Batra (Uppsala, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Acute coronary syndromes: diagnosis, outcomes, and predictors

The Event

Event poster

ESC Congress 2024

31 August 2024 16:00 CET
You may be interested in
thumbnail
Congress Presentation
High apo-CIII level correlates with poor lipid status, pro-inflammatory and fibrotic biomarker profile, and adverse cardiovascular outcome in patients with recent acute coronary syndrome
thumbnail
Congress Presentation
Elevated lipoprotein(a) identifies patients with acute coronary syndrome who derive earlier and greater cardiovascular benefit of alirocumab, particularly for limb events
thumbnail
Congress Session
Smaller trials, trial updates, and other studies on lipid therapy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources